This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.10% per year. These returns cover a period from January 1, 1988 through October 7, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Is Ingevity (NGVT) a Great Value Stock Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Wall Street Analysts Predict a 40% Upside in Ingevity (NGVT): Here's What You Should Know
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 39.7% in Ingevity (NGVT). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Ingevity's (NGVT) Q4 Earnings and Revenues Beat Estimate
by Zacks Equity Research
Ingevity's (NGVT) Q4 results benefit from higher volumes in the Performance Chemicals segment.
Ingevity (NGVT) Surpasses Q4 Earnings and Revenue Estimates
by Zacks Equity Research
Ingevity (NGVT) delivered earnings and revenue surprises of 9.86% and 15.27%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Livent (LTHM) Tops Q4 Earnings and Revenue Estimates
by Zacks Equity Research
Livent (LTHM) delivered earnings and revenue surprises of 14.29% and 17.65%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Ingevity's (NGVT) Earnings and Sales Beat Estimates in Q3
by Zacks Equity Research
Ingevity's (NGVT) third-quarter results benefit from higher demand and price increases in its Performance Chemicals business.
Ingevity (NGVT) Q3 Earnings and Revenues Top Estimates
by Zacks Equity Research
Ingevity (NGVT) delivered earnings and revenue surprises of 6.58% and 5.40%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate Ingevity (NGVT) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Ingevity (NGVT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Ingevity (NGVT) to Boost Monomer Capacity Due to Demand Surge
by Zacks Equity Research
Ingevity (NGVT) to boost caprolactone monomer production at its Warrington unit to more effectively cater to the rising demand in its engineered polymers portfolio.
Ida, Supply Constraints Dent US Chemicals as August Output Dips
by Anindya Barman
The August reading showed lower production on a monthly comparison basis across all regions barring Northeast, reflecting the impacts of Hurricane Ida and supply-chain disruptions.
Ingevity (NGVT) Down 9.2% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Ingevity (NGVT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Ingevity (NGVT) Up 14% in 6 Months: What's Driving the Stock?
by Zacks Equity Research
Ingevity (NGVT) is gaining from acquisitions and strength in activated carbon demand.
Ingevity (NGVT) Upgraded to Buy: What Does It Mean for the Stock?
by Zacks Equity Research
Ingevity (NGVT) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Ingevity's (NGVT) Earnings and Sales Top Estimates in Q2
by Zacks Equity Research
Ingevity (NGVT) benefits from higher demand and price increases across its business in the second quarter.
Ingevity (NGVT) Q2 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Ingevity (NGVT) delivered earnings and revenue surprises of 28.10% and 8.10%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Ingevity (NGVT) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
by Zacks Equity Research
Ingevity (NGVT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Ingevity's (NGVT) Stock Up 14% in 3 Months: Here's Why
by Zacks Equity Research
Ingevity (NGVT) experiences steady price rise due to gains from acquisitions, increased revenues in China and a rise in automotive-based activated carbon sales.
Here's Why You Should Buy Ingevity (NGVT) Stock Right Now
by Zacks Equity Research
Ingevity (NGVT) gains from acquisitions, increased sales in China and a rise in automotive-based activated carbon sales.
U.S. Specialty Chemical Rebound Continues as May Volume Rises
by Anindya Barman
U.S. specialty chemical volumes ticked up 0.7% in May as the industry continues its recovery after being hit by the winter storm in the U.S. Gulf Coast earlier this year.
5 Top Specialty Chemical Stocks to Buy on End-Market Strength
by Anindya Barman
An upturn in demand across major end-markets such as construction and automotive instills optimism in the specialty chemical space. VVV, ESI, NGVT, AXTA and KWR are worth betting on right now.
Why You Should Add Ingevity (NGVT) Stock to Your Portfolio
by Zacks Equity Research
Ingevity (NGVT) benefits from regulation-driven adoption of its applications and cost-control actions.
American Vanguard (AVD) to Acquire Envoke Herbicide From Syngenta
by Zacks Equity Research
The addition of Envoke to American Vanguard's (AVD) unit AMVAC's portfolio allows it to reinforce its portfolio in core crops.
Ingevity (NGVT) Announces Price Hike of Chemical-Based Products
by Zacks Equity Research
Ingevity's (NGVT) price hike is due to continued strong market demand as well as rising raw materials and logistics costs.
Ingevity (NGVT) Is Up 7.02% in One Week: What You Should Know
by Zacks Equity Research
Does Ingevity (NGVT) have what it takes to be a top stock pick for momentum investors? Let's find out.
Valvoline (VVV) Hits 52-Week High, Can the Run Continue?
by Zacks Equity Research
Valvoline (VVV) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.